ARDX
Ardelyx Inc
NASDAQ · Biotechnology
$7.32
+0.32 (+4.57%)
Open$7.15
Previous Close$7.00
Day High$7.34
Day Low$6.99
52W High$8.40
52W Low$3.21
Volume—
Avg Volume3.05M
Market Cap1.78B
P/E Ratio—
EPS$-0.24
SectorBiotechnology
Analyst Ratings
Strong Buy
17 analysts
Price Target
+544.0% upside
Current
$7.32
$7.32
Target
$47.14
$47.14
$33.22
$47.14 avg
$55.45
Key Financials
| FY 2026 | FY 2025 | FY 2024 | |
|---|---|---|---|
| Revenue | 344.59M | 628.50M | 556.78M |
| Net Income | -40,430,926 | -29,854,842 | -22,621,785 |
| Profit Margin | -11.7% | -4.8% | -4.1% |
| EBITDA | -24,589,000 | -37,891,031 | -31,484,723 |
| Free Cash Flow | — | -23,199,305 | -21,445,059 |
| Rev Growth | +220.9% | +14.6% | +16.2% |
| Debt/Equity | 0.87 | 0.41 | 0.37 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $223.43 | +2.01% | 165.4 | 394.89B |
| AMGN | Amgen Inc | $384.32 | +4.49% | 26.8 | 206.95B |
| GILD | Gilead Sciences Inc | $152.50 | +2.10% | 23.3 | 189.20B |
| VRTX | Vertex Pharmaceuticals Inc | $477.92 | +4.17% | 33.7 | 123.82B |
| REGN | Regeneron Pharmaceuticals | $785.51 | +2.46% | 18.4 | 83.03B |
| ALNY | Alnylam Pharmaceuticals Inc | $328.16 | -0.93% | 995.2 | 43.35B |